We’re thrilled to announce that Biocytogen will attend TIDES USA 2026 in Boston, MA from May 11th - 14th. There will be 1900+ attendees, from biopharma, gathering to discuss the latest genome editing technologies and targeted device-based delivery strategies. Visit booth #K1 to meet our experts and learn about how we support best practices in drug development with our innovative platforms.
What is TIDES USA 2026?
TIDES (Therapeutic Innovations in Drug Engineering and Synthesis) USA 2026 is a premier conference that brings together top scientists and industry professionals across the fields of oligonucleotide, peptide, mRNA, genome editing, and drug delivery therapeutics. The four day program will cover everything from pre-clinical considerations to the future of function and delivery.
Event Overview
Date: May 11th - 14th, 2026
Venue: Hynes Convention Center, 900 Boylston St, Boston, MA 02115
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to collaborating with you in Boston, MA!
